Published in Support Care Cancer on August 06, 2008
Bone cancer pain. Ann N Y Acad Sci (2010) 1.28
Farnesyl pyrophosphate is a novel pain-producing molecule via specific activation of TRPV3. J Biol Chem (2010) 1.17
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer (2013) 1.12
Balloon kyphoplasty in malignant spinal fractures: a systematic review and meta-analysis. BMC Palliat Care (2009) 1.01
Bone cancer pain: from mechanism to therapy. Curr Opin Support Palliat Care (2014) 0.89
Pathogenesis and clinical aspects of pain in patients with osteoporosis. Clin Cases Miner Bone Metab (2014) 0.80
Nociceptive and pro-inflammatory effects of dimethylallyl pyrophosphate via TRPV4 activation. Br J Pharmacol (2012) 0.79
Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Support Care Cancer (2014) 0.78
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg (2005) 7.36
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg (2004) 6.38
Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst (2005) 4.51
Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc (2005) 4.02
Bone imaging in metastatic breast cancer. J Clin Oncol (2004) 3.85
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol (2003) 3.73
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol (2007) 3.51
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med (1996) 3.41
Bisphosphonates for breast cancer. Cochrane Database Syst Rev (2005) 3.24
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol (2005) 3.09
Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol (2007) 3.02
Malignant bone pain: pathophysiology and treatment. Pain (1997) 2.75
Bisphosphonates: clinical experience. Oncologist (2004) 2.12
Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol (2001) 2.10
Therapy of metastatic bone pain. J Nucl Med (2001) 1.94
Renal failure with the use of zoledronic acid. N Engl J Med (2003) 1.89
Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia (2005) 1.75
Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev (2002) 1.73
Pathophysiology of bone cancer pain. J Support Oncol (2005) 1.68
Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage (2004) 1.67
Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. Cochrane Database Syst Rev (2004) 1.65
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica (2006) 1.49
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol (2006) 1.47
Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int (2003) 1.45
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol (2003) 1.35
Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int (1999) 1.31
Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol (1998) 1.27
Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care (2004) 1.22
Cancer pain management by radiotherapists: a survey of radiation therapy oncology group physicians. Int J Radiat Oncol Biol Phys (2000) 1.14
Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med (1999) 1.10
Bone metastases: approaches to management. Semin Oncol (2001) 1.08
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain (2004) 1.08
Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer (2001) 1.07
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer (2004) 1.04
Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol (2001) 1.02
Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases - an evidence-based practice guideline. BMC Cancer (2004) 1.02
[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull Cancer (2001) 1.02
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat (2007) 1.02
Malignant bone pain: pathophysiology and treatments. Curr Rev Pain (2000) 1.01
Pain control by ionizing radiation of bone metastasis. Int J Dev Biol (2004) 0.99
Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev (2000) 0.99
Biology of bone metastases: causes and consequences. Clin Breast Cancer (2007) 0.98
Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol (2001) 0.98
Acrylic bone cements: mechanical and physical properties. Orthop Clin North Am (2005) 0.97
Treatment of painful osteoporotic or traumatic vertebral compression fractures by percutaneous vertebral augmentation procedures: a nonrandomized comparison between vertebroplasty and kyphoplasty. Clin J Pain (2007) 0.97
Balloon kyphoplasty for the treatment of pathological fractures in the thoracic and lumbar spine caused by metastasis: one-year follow-up. Acta Radiol (2007) 0.97
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol (2002) 0.97
Percutaneous vertebroplasty in patients with intractable pain from osteoporotic or metastatic fractures: A prospective study using quality-of-life assessment. Can Assoc Radiol J (2006) 0.96
Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol (2006) 0.95
Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol (1995) 0.94
Biology of bone cancer pain. Clin Cancer Res (2006) 0.94
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun (2007) 0.93
Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol (2001) 0.92
The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol (2001) 0.92
PMMA to stabilize bone and deliver antineoplastic and antiresorptive agents. Clin Orthop Relat Res (2003) 0.92
The role of bisphosphonates in hormone-refractory prostate cancer. World J Urol (2005) 0.91
Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev (2003) 0.90
Treatment of painful compression vertebral fractures with vertebroplasty: results and complications. Radiol Med (2005) 0.90
Antiepileptic drugs in the treatment of neuropathic pain. Drugs (2007) 0.90
Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev (2003) 0.88
Factors influencing the use of single vs multiple fractions of palliative radiotherapy for bone metastases: a 5-year review. Clin Oncol (R Coll Radiol) (2005) 0.88
Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol (2006) 0.87
Bisphosphonates and metastatic breast carcinoma. Cancer (2003) 0.87
Physiological bases of bone regeneration II. The remodeling process. Med Oral Patol Oral Cir Bucal (2006) 0.85
Practice guidelines for transdermal opioids in malignant pain. Drugs (2004) 0.84
Maintained pain reduction in five patients with multiple myeloma 12 months after treatment of the involved cervical vertebrae with vertebroplasty. Acta Radiol (2006) 0.84
Bisphosphonates in the treatment of metastatic breast cancer. J Mammary Gland Biol Neoplasia (2001) 0.84
Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage (2004) 0.84
The use of bisphosphonates in patients with breast cancer. Cancer Control (2003) 0.83
High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer (1997) 0.83
Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis (2003) 0.83
Preclinical perspectives on bisphosphonate renal safety. Oncologist (2005) 0.82
The use of palliative radiotherapy in the management of breast cancer. Eur J Cancer (1992) 0.82
A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys (1992) 0.82
Controversies in pharmacotherapy of pain management. Lancet Oncol (2005) 0.82
Clinical application of the World Health Organization analgesic ladder. J Intraven Nurs (2002) 0.81
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig (2006) 0.81
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother (2005) 0.79
Bone metastases in breast cancer. Curr Treat Options Oncol (2003) 0.78
Healing focal "flare" phenomenon after radiotherapy in a bone metastasis from bladder cancer. Clin Nucl Med (2005) 0.76
Clodronate: a review of its use in breast cancer. Drugs Aging (1999) 0.76
Usefulness of bone formation markers in breast cancer. Int J Biol Markers (2005) 0.76
The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res (1998) 0.76
Bisphosphonates for metastatic bone pain. Support Care Cancer (1999) 0.75
Promoting science in a pragmatic world: not (yet) time for partial opioid rotation. Support Care Cancer (2005) 0.75
Scoring the effect of radiotherapy for painful bone metastases. Support Care Cancer (2006) 0.75
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. J Clin Oncol (2009) 3.36
A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell (2006) 3.10
Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood (2002) 2.61
Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol (2003) 2.38
Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med (2003) 2.36
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol (2009) 2.09
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.86
Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N Engl J Med (2007) 1.74
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci U S A (2011) 1.59
Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy? J Pain Symptom Manage (2012) 1.54
Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J Pain Symptom Manage (2012) 1.50
CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood (2003) 1.46
p53-dependent inhibition of FKHRL1 in response to DNA damage through protein kinase SGK1. Proc Natl Acad Sci U S A (2004) 1.43
Primary manifestation of small lymphocytic lymphoma in the prostate. Onkologie (2009) 1.41
Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol (2011) 1.41
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol (2004) 1.32
Consensus-based standards for best supportive care in clinical trials in advanced cancer. Lancet Oncol (2012) 1.23
The use of photon beams of a flattening filter-free linear accelerator for hypofractionated volumetric modulated arc therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys (2012) 1.16
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol (2013) 1.15
A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manage (2010) 1.15
Fatigue in palliative care patients -- an EAPC approach. Palliat Med (2008) 1.12
Treatment sequencing in metastatic castrate-resistant prostate cancer. Asian J Androl (2014) 1.12
A randomized, controlled trial of physician postures when breaking bad news to cancer patients. Palliat Med (2007) 1.12
Evolving classification systems for cancer cachexia: ready for clinical practice? Support Care Cancer (2010) 1.10
Symptom assessment in palliative care: a need for international collaboration. J Clin Oncol (2008) 1.07
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol (2008) 1.05
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother (2006) 1.04
Effect of high dose per pulse flattening filter-free beams on cancer cell survival. Radiother Oncol (2011) 1.01
Ckap2 regulates aneuploidy, cell cycling, and cell death in a p53-dependent manner. Cancer Res (2005) 1.00
Tyrosine phosphorylation by Src within the cavity of the adenine nucleotide translocase 1 regulates ADP/ATP exchange in mitochondria. Am J Physiol Cell Physiol (2009) 0.98
Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage (2004) 0.96
Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. J Clin Oncol (2009) 0.96
CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp Dermatol (2005) 0.96
Consensus on cachexia definitions. J Am Med Dir Assoc (2010) 0.95
The association between autonomic dysfunction and survival in male patients with advanced cancer: a preliminary report. J Pain Symptom Manage (2010) 0.94
Trigger-dependent gene expression profiles in cardiac preconditioning: evidence for distinct genetic programs in ischemic and anesthetic preconditioning. Anesthesiology (2004) 0.94
Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study. J Cachexia Sarcopenia Muscle (2013) 0.94
Development of symptom assessments utilising item response theory and computer-adaptive testing--a practical method based on a systematic review. Crit Rev Oncol Hematol (2010) 0.93
A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med (2003) 0.93
Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case Rep Oncol (2012) 0.93
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol (2005) 0.92
Identification of factors associated with fatigue in advanced cancer: a subset analysis of the European palliative care research collaborative computerized symptom assessment data set. J Pain Symptom Manage (2011) 0.91
Stem cell-like human endothelial progenitors show enhanced colony-forming capacity after brief sevoflurane exposure: preconditioning of angiogenic cells by volatile anesthetics. Anesth Analg (2009) 0.90
Generation and characterization of the Anp32e-deficient mouse. PLoS One (2010) 0.89
P-selectin genotype is associated with the development of cancer cachexia. EMBO Mol Med (2012) 0.89
Identification of BERP (brain-expressed RING finger protein) as a p53 target gene that modulates seizure susceptibility through interacting with GABA(A) receptors. Proc Natl Acad Sci U S A (2010) 0.89
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood (2007) 0.89
Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med (2012) 0.88
Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: three peas in a pod? - analysis from a multicenter cross sectional study. Acta Oncol (2013) 0.88
Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer (2013) 0.88
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res (2014) 0.88
Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2012) 0.88
Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods (2004) 0.88
International Association for Hospice and Palliative Care (IAHPC) List of Essential Practices in Palliative Care. J Pain Palliat Care Pharmacother (2012) 0.88
Perception of discomfort by relatives and nurses in unresponsive terminally ill patients with cancer: a prospective study. J Pain Symptom Manage (2003) 0.87
Helium breathing provides modest antiinflammatory, but no endothelial protection against ischemia-reperfusion injury in humans in vivo. Anesth Analg (2009) 0.87
Cachexia assessment tools. Curr Opin Support Palliat Care (2011) 0.87
Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. Oncologist (2008) 0.87
Ghrelin-induced hypothermia: a physiological basis but no clinical risk. Physiol Behav (2011) 0.86
How well is palliative care integrated into cancer care? A MASCC, ESMO, and EAPC Project. Support Care Cancer (2015) 0.86
Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. Eur Urol (2011) 0.86
The changing causal foundations of cancer-related symptom clustering during the final month of palliative care: a longitudinal study. BMC Med Res Methodol (2008) 0.85
Cardiac remodelling hinders activation of cyclooxygenase-2, diminishing protection by delayed pharmacological preconditioning: role of HIF1 alpha and CREB. Cardiovasc Res (2008) 0.85
Thalidomide: from tragedy to promise. Swiss Med Wkly (2003) 0.85
Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie (2007) 0.84
Patient-focused endpoints in advanced cancer: criterion-based validation of accelerometer-based activity monitoring. Clin Nutr (2011) 0.84
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res (2012) 0.83
Expert conference on cancer pain assessment and classification--the need for international consensus: working proposals on international standards. BMJ Support Palliat Care (2011) 0.83
Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort. Swiss Med Wkly (2010) 0.83
Computer-based symptom assessment is feasible in patients with advanced cancer: results from an international multicenter study, the EPCRC-CSA. J Pain Symptom Manage (2012) 0.82
Extraneural spread of glioblastoma--report of two cases. Onkologie (2008) 0.81
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med (2013) 0.81
The CPT1C 5'UTR contains a repressing upstream open reading frame that is regulated by cellular energy availability and AMPK. PLoS One (2011) 0.80
Management of von hippel-lindau disease: an interdisciplinary review. Oncol Res Treat (2014) 0.80
Concordant colon tumors in monozygotic twins previously treated for prostate cancer. Fam Cancer (2008) 0.80
Increased bone marrow activity on F-18-FDG PET/CT in granulocyte colony stimulating factor producing anaplastic thyroid carcinoma. Clin Nucl Med (2010) 0.80
Is there a genetic cause of appetite loss?-an explorative study in 1,853 cancer patients. J Cachexia Sarcopenia Muscle (2012) 0.79
Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. Urol Int (2009) 0.79
An overview of the European Society of Medical Oncology (ESMO) Symposium on Cancer and Nutrition 2009: from cancer prevention to nutrition support to alleviating suffering in patients with advanced cancer. Support Care Cancer (2011) 0.78
MASCC/ESMO/EAPC survey of palliative programs. Support Care Cancer (2014) 0.78
Management of bone metastases in patients with castration-resistant prostate cancer. Urol Int (2014) 0.77
The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage (2003) 0.77
Von Hippel-Lindau disease--a rare disease important to recognize. Onkologie (2005) 0.77
Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology. J Proteome Res (2016) 0.77
Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib. Diabetes Care (2010) 0.76
Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. Prostate (2005) 0.76
Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective. Curr Opin Support Palliat Care (2015) 0.76
The silent symptom early satiety: a forerunner of distinct phenotypes of anorexia/cachexia syndromes. Support Care Cancer (2006) 0.75
A rare but severe pulmonary side effect of cetuximab in two patients. BMJ Case Rep (2012) 0.75
Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC. BMC Palliat Care (2012) 0.75
Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol (2011) 0.75
Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor. J Clin Oncol (2013) 0.75
Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie (2011) 0.75
Psychosocial consequences of cancer cachexia: the development of an item bank. J Pain Symptom Manage (2013) 0.75